Evidence map›Paper›PMID 23380715›Full record

ArticleBiological psychiatry2013

A clinical risk stratification tool for predicting treatment resistance in major depressive disorder.

Roy H Perlis

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Biological psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04234776 (Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression), which is not on this map. Cited by 78 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 7 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04234776 phase4unknown statusnot on this mapstarted 2018, after this paper: background citation

Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression

TypeinterventionalSponsorUniversity of Sao PauloRan2018 to 2021Enrolled88ConditionsDepressive DisorderArmsKetamine, Cognition, Suicide risk, Depression thoughts, Quality of life and disability
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 7 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Roy H PerlisCenter for Experimental Drugs and Diagnostics, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. rperlis@partners.org
Center for Human Genetics · US

Funding

Building a Risk Stratification Model for Treatment Resistance in Major DepressiveR01MH086026 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI PERLIS, ROY H. · 2009 to 2011
$1.3M
TREATMENT RESISTANT DEPRESSION-278990003N01MH090003 · NIMH · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · 1999 to 2003
–
NIMH NIH HHS MH086026NIMH NIH HHS N01 MH090003NIMH NIH HHS N01 MH-90003NIMH NIH HHS R01 MH086026
6 · The paper itself

Abstract

backgroundEarly identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice.

methodsData were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials.

resultsA logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches--a naïve Bayes classifier and a support vector machine, and a random forest model--was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk.

conclusionRisk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.

Indexed as

Decision Support TechniquesAdolescentAdultAgedArtificial IntelligenceCohort StudiesDepressive Disorder, Treatment-ResistantFemaleHumansLogistic ModelsMajor Depressive DisorderMaleMiddle AgedMultivariate AnalysisYoung Adult

Identifiers

PMID23380715
PMCPMC3690142
OpenAlexW2056841881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.